Disease-modifying therapy in MS: a critical review of the literature Douglas S. Goodin OriginalPaper Pages: v3 - v11
What do we know about the mechanism of action of disease-modifying treatments in MS? Hans-Peter HartungAmit Bar-OrYannis Zoukos OriginalPaper Pages: v12 - v29
Optimising MS disease-modifying therapies: antibodies in perspective Gavin Giovannoni OriginalPaper Pages: v30 - v35
Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS Gordon S. Francis OriginalPaper Pages: v42 - v49
Disease-modifying therapy in MS: a critical review of the literature Douglas S. Goodin OriginalPaper Pages: v50 - v56
Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? Ludwig KapposJens KuhleErnst-Wilhelm Radue OriginalPaper Pages: v57 - v64
Predicting the course of relapsing-remitting MS using longitudinal disability curves Anat Achiron OriginalPaper Pages: v65 - v68
Treatment optimisation in MS: progress to date and goals for the future David Bates OriginalPaper Pages: v88 - v89